374 related articles for article (PubMed ID: 33449299)
1. Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality.
Philippe A; Chocron R; Gendron N; Bory O; Beauvais A; Peron N; Khider L; Guerin CL; Goudot G; Levasseur F; Peronino C; Duchemin J; Brichet J; Sourdeau E; Desvard F; Bertil S; Pene F; Cheurfa C; Szwebel TA; Planquette B; Rivet N; Jourdi G; Hauw-Berlemont C; Hermann B; Gaussem P; Mirault T; Terrier B; Sanchez O; Diehl JL; Fontenay M; Smadja DM
Angiogenesis; 2021 Aug; 24(3):505-517. PubMed ID: 33449299
[TBL] [Abstract][Full Text] [Related]
2. Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance.
Philippe A; Gendron N; Bory O; Beauvais A; Mirault T; Planquette B; Sanchez O; Diehl JL; Chocron R; Smadja DM
Angiogenesis; 2021 Aug; 24(3):407-411. PubMed ID: 33974165
[TBL] [Abstract][Full Text] [Related]
3. The ADAMTS13-von Willebrand factor axis in COVID-19 patients.
Mancini I; Baronciani L; Artoni A; Colpani P; Biganzoli M; Cozzi G; Novembrino C; Boscolo Anzoletti M; De Zan V; Pagliari MT; Gualtierotti R; Aliberti S; Panigada M; Grasselli G; Blasi F; Peyvandi F
J Thromb Haemost; 2021 Feb; 19(2):513-521. PubMed ID: 33230904
[TBL] [Abstract][Full Text] [Related]
4. Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19.
Marco A; Marco P
J Thromb Thrombolysis; 2021 Aug; 52(2):497-503. PubMed ID: 33866481
[TBL] [Abstract][Full Text] [Related]
5. Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation.
Ward SE; Curley GF; Lavin M; Fogarty H; Karampini E; McEvoy NL; Clarke J; Boylan M; Alalqam R; Worrall AP; Kelly C; de Barra E; Glavey S; Ni Cheallaigh C; Bergin C; Martin-Loeches I; Townsend L; Mallon PW; O'Sullivan JM; O'Donnell JS;
Br J Haematol; 2021 Feb; 192(4):714-719. PubMed ID: 33326604
[TBL] [Abstract][Full Text] [Related]
6. Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality.
Sinkovits G; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Mező B; Csuka D; Hurler L; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Prohászka Z
Thromb Haemost; 2022 Feb; 122(2):240-256. PubMed ID: 35062036
[TBL] [Abstract][Full Text] [Related]
7. ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy.
Henry BM; Benoit SW; de Oliveira MHS; Lippi G; Favaloro EJ; Benoit JL
Int J Lab Hematol; 2021 Jul; 43 Suppl 1(Suppl 1):129-136. PubMed ID: 33270980
[TBL] [Abstract][Full Text] [Related]
8. Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19?
Ladikou EE; Sivaloganathan H; Milne KM; Arter WE; Ramasamy R; Saad R; Stoneham SM; Philips B; Eziefula AC; Chevassut T
Clin Med (Lond); 2020 Sep; 20(5):e178-e182. PubMed ID: 32694169
[TBL] [Abstract][Full Text] [Related]
9. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
[TBL] [Abstract][Full Text] [Related]
10. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study.
Goshua G; Pine AB; Meizlish ML; Chang CH; Zhang H; Bahel P; Baluha A; Bar N; Bona RD; Burns AJ; Dela Cruz CS; Dumont A; Halene S; Hwa J; Koff J; Menninger H; Neparidze N; Price C; Siner JM; Tormey C; Rinder HM; Chun HJ; Lee AI
Lancet Haematol; 2020 Aug; 7(8):e575-e582. PubMed ID: 32619411
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory and Prothrombotic Biomarkers Associated With the Severity of COVID-19 Infection.
Lopez-Castaneda S; García-Larragoiti N; Cano-Mendez A; Blancas-Ayala K; Damian-Vázquez G; Perez-Medina AI; Chora-Hernández LD; Arean-Martínez C; Viveros-Sandoval ME
Clin Appl Thromb Hemost; 2021; 27():1076029621999099. PubMed ID: 33835872
[TBL] [Abstract][Full Text] [Related]
12. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
13. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis.
Andrianto ; Al-Farabi MJ; Nugraha RA; Marsudi BA; Azmi Y
Microvasc Res; 2021 Nov; 138():104224. PubMed ID: 34273359
[TBL] [Abstract][Full Text] [Related]
15. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID-19.
Rauch A; Labreuche J; Lassalle F; Goutay J; Caplan M; Charbonnier L; Rohn A; Jeanpierre E; Dupont A; Duhamel A; Faure K; Lambert M; Kipnis E; Garrigue D; Lenting PJ; Poissy J; Susen S
J Thromb Haemost; 2020 Nov; 18(11):2942-2953. PubMed ID: 32881304
[TBL] [Abstract][Full Text] [Related]
16. Von Willebrand Factor, ADAMTS13, and the Risk of Mortality: The Rotterdam Study.
Sonneveld MA; Franco OH; Ikram MA; Hofman A; Kavousi M; de Maat MP; Leebeek FW
Arterioscler Thromb Vasc Biol; 2016 Dec; 36(12):2446-2451. PubMed ID: 27737864
[TBL] [Abstract][Full Text] [Related]
17. Von Willebrand factor in relation to coronary plaque characteristics and cardiovascular outcome. Results of the ATHEROREMO-IVUS study.
Sonneveld MA; Cheng JM; Oemrawsingh RM; de Maat MP; Kardys I; Garcia-Garcia HM; van Geuns RJ; Regar E; Serruys PW; Boersma E; Akkerhuis KM; Leebeek FW
Thromb Haemost; 2015 Mar; 113(3):577-84. PubMed ID: 25472874
[TBL] [Abstract][Full Text] [Related]
18. Placental growth factor level in plasma predicts COVID-19 severity and in-hospital mortality.
Smadja DM; Philippe A; Bory O; Gendron N; Beauvais A; Gruest M; Peron N; Khider L; Guerin CL; Goudot G; Levavasseur F; Duchemin J; Pene F; Cheurfa C; Szwebel TA; Sourdeau E; Planquette B; Hauw-Berlemont C; Hermann B; Gaussem P; Samama CM; Mirault T; Terrier B; Sanchez O; Rance B; Fontenay M; Diehl JL; Chocron R
J Thromb Haemost; 2021 Jul; 19(7):1823-1830. PubMed ID: 33830623
[TBL] [Abstract][Full Text] [Related]
19. Increased thrombin generation and platelet activation are associated with deficiency in high molecular weight multimers of von Willebrand factor in patients with moderate-to-severe aortic stenosis.
Natorska J; Bykowska K; Hlawaty M; Marek G; Sadowski J; Undas A
Heart; 2011 Dec; 97(24):2023-8. PubMed ID: 21561895
[TBL] [Abstract][Full Text] [Related]
20. Comparative assessment of von Willebrand factor multimers vs activity for von Willebrand disease using modern contemporary methodologies.
Favaloro EJ; Oliver S; Mohammed S; Vong R
Haemophilia; 2020 May; 26(3):503-512. PubMed ID: 32159272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
